On Mar. 5, 2020, BioReference Laboratories, an OPKO Health company, announced it was offering a test for the novel coronavirus (2019-nCoV). With an extensive network of patient service centers and a national logistic network, BioReference provided expanded access to a COVID-19 testing across the U.S.

BioReference has collaborated with the U.S. Centers for Disease Control and Prevention, the World Health Organization and other public health agencies to help identify and develop diagnostic tests for emerging infectious diseases.

BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. The company is in network with the five largest health plans in the United States, operates a network of 10 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists.